Skip to main content
Supriya Lifescience Limited logo

Supriya Lifescience Limited — Investor Relations & Filings

Ticker · SUPRIYA ISIN · INE07RO01027 LEI · 894500RBVJX1EOJP0Y02 BSE.NS Manufacturing
Open in API
Filings indexed 475 across all filing types
Latest filing 2023-03-13 Investor Presentation
Country IN India
Listing BSE.NS SUPRIYA

About Supriya Lifescience Limited

https://www.supriyalifescience.com

Supriya Lifescience Limited is a research-driven manufacturer of Active Pharmaceutical Ingredients (APIs) with a focus on diverse therapeutic segments. The company specializes in the production of antihistamines, anti-allergics, vitamins, anesthetics, and anti-asthmatics. Its core product portfolio includes Chlorpheniramine Maleate, Ketamine Hydrochloride, and Salbutamol Sulphate, maintaining a significant global market share in these niche categories. Operating with a strong emphasis on backward integration, the firm ensures supply chain reliability and cost efficiency. The manufacturing infrastructure is compliant with international regulatory standards, including approvals from the USFDA, EDQM, and PMDA. Supriya Lifescience serves a broad international clientele across more than 100 countries, catering to both regulated and semi-regulated markets through its advanced R&D capabilities and commitment to quality excellence.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation Classification · 90% confidence The document is a letter addressed to stock exchanges informing about a scheduled Analyst/Institutional Investor meeting via video conference. It mentions that an Investor Presentation has been uploaded on the company's website and stock exchanges. The document is short (2466 characters) and serves as a notification of the meeting and the availability of the presentation, rather than containing the presentation itself or detailed financial data. This fits the description of an Investor Presentation announcement but since the actual presentation is not included, and the document is primarily an announcement of the meeting and presentation availability, it aligns best with the category of Investor Presentation (IP).
2023-03-13 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges informing about a scheduled meeting between company officials and analysts/institutional investors. It mentions that an Investor Presentation has been uploaded on the company's website and stock exchanges. The document is short (2468 characters) and serves as an announcement of the meeting and the availability of the presentation, rather than containing the presentation or detailed financial data itself. Therefore, it is not the Investor Presentation report but an announcement related to it. According to the classification rules, such announcements are best classified as Regulatory Filings (RNS) since it does not fit other specific categories and is a regulatory disclosure under SEBI Listing Regulations.
2023-03-09 English
Reply to Clarification- Financial results
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the National Stock Exchange of India regarding a clarification about the company's financial results. It confirms the business segment of Supriya Lifescience Limited but does not contain any financial data, detailed results, or report content. The document is short (1756 characters) and serves as a clarification or regulatory communication rather than a financial report or announcement of results. It does not fit into categories like Annual Report, Earnings Release, or Interim Report. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement or compliance communication without substantive financial data.
2023-02-28 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a detailed transcript of an earnings conference call for Q3 and nine months FY2023 of Supriya Lifescience Limited. It includes management commentary, financial performance highlights, forward-looking statements, and a Q&A session with investors. The text explicitly mentions it is a transcript of the earnings call held on February 15, 2023, discussing operational and financial performance for the quarter and nine months ended December 31, 2022. This matches the definition of a Call Transcript (CT), which is a full text transcript of company conference calls such as earnings calls with Q&A. The document is lengthy (15,000 characters), contains substantive financial data and management discussion, and is not merely an announcement or summary. Therefore, the correct classification is CT with high confidence.
2023-02-20 English
Updates
Board/Management Information Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) providing details of Key Managerial Personnel (KMP) pursuant to Regulation 30(5) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It is an announcement of management personnel information for regulatory disclosure purposes. There is no financial data, no report or presentation, no voting results, no legal proceedings, no capital changes, and no earnings information. The content fits best under Board/Management Information (MANG) as it relates to disclosure of key management personnel details.
2023-02-15 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter dated February 15, 2023, addressed to stock exchanges (BSE and NSE) informing them about the availability of the audio recording of the company's earnings call for the third quarter and nine months ended FY 2022-2023. It references the earnings call and provides a link to the recording on the company's website. The document does not contain the transcript or detailed financial data itself but is an announcement about the earnings call recording availability. Given the short length (2204 characters) and the nature of the content (informing about the earnings call recording), this fits best as a Regulatory Filing (RNS) rather than a full Call Transcript (CT) or Earnings Release (ER).
2023-02-15 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.